secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0000950170-23-010755
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo reports 2022 net income of $8.0M on $37.2M gain; cash down to $22.6M
---------------------------------------------------------------------------

- Net income of $8.0M ($1.57 diluted EPS) vs net loss of $28.5M in 2021; includes $37.2M gain on extinguishment of royalty liability.
- Royalty revenue fell to $3.1M from $12.3M due to amendment of royalty purchase agreement with HCR.
- Cash and equivalents $22.6M at Dec 31, 2022, down from $45.0M a year earlier.
- APVO436 Phase 1b data showed activity in AML; Phase 2 planned for 2H23. ALG.APV-527 Phase 1 first patient dosed Feb 2023.
- Preclinical candidate APV0711 (anti-PD-L1/anti-CD40) filed provisional patent; preclinical studies initiated Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017023010755/0000950170-23-010755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017023010755/apvo-20230330.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer